Immunogenicity is a major problem with protein-based therapeutics due to circulating anti-drug antibody (ADA) production. ADA may lead to many clinical problems including allergic reactions, altered pharmacokinetic, reduced efficacy, etc.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.